EPRX (Eupraxia Pharmaceuticals, Inc.) יחס שווי שוק לשווי בספרים
Eupraxia Pharmaceuticals (EPRX) automates the production of extended-release agents by combining robotic lines with expert clinical process management. The startup is currently preparing its depot drug platform for market entry, finalizing tests and selecting distributors. The indicator stands at 4.82. Historical price action demonstrates the potential of prolongation technologies, which transform proven molecules into stable cash cows.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_EPRX_-_Eupraxia-Pharmaceuticals_-_Market-Capitalization-to-Net-Assets "EPRX יחס שווי שוק לערך בספרים Eupraxia Pharmaceuticals Inc. (06.04.2024 - 29.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Eupraxia Pharmaceuticals (EPRX)
Eupraxia Pharmaceuticals is transforming rehabilitation through its DiffuCORE technology, providing a prolonged analgesic effect for Librexia. The price-to-book ratio determines the size of the investment premium over assets, reflecting market confidence in the company's intellectual property, which allows for an assessment of correction risk through the historical price-to-book trend.